ASCO Names John Durant, MD, as Executive VP and Washington Lobbyist

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WASHINGTON--John Durant, MD, has been named to the newly created position of executive vice president of the American Society of Clinical Oncology (ASCO). Formerly president of ASCO and a member of its board of directors, Dr. Durant will become the society's leading spokesman and advocate in Washington on April 1. He is currently vice president for health affairs and director of the medical school at the University of Alabama at Birmingham.

WASHINGTON--John Durant, MD, has been named to the newly createdposition of executive vice president of the American Society ofClinical Oncology (ASCO). Formerly president of ASCO and a memberof its board of directors, Dr. Durant will become the society'sleading spokesman and advocate in Washington on April 1. He iscurrently vice president for health affairs and director of themedical school at the University of Alabama at Birmingham.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.